CBL-514 Injection
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Subcutaneous Fat
Conditions
Subcutaneous Fat
Trial Timeline
Feb 14, 2022 → Mar 22, 2023
NCT ID
NCT04897412About CBL-514 Injection
CBL-514 Injection is a phase 2 stage product being developed by Caliway Biopharmaceuticals for Subcutaneous Fat. The current trial status is completed. This product is registered under clinical trial identifier NCT04897412. Target conditions include Subcutaneous Fat.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07140939 | Phase 3 | Recruiting |
| NCT05736107 | Phase 2 | Completed |
| NCT05836779 | Phase 2 | Completed |
| NCT04897412 | Phase 2 | Completed |
Competing Products
9 competing products in Subcutaneous Fat
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TR-701 FA + Linezolid | Merck | Phase 3 | 77 |
| TR-701 FA + Linezolid | Merck | Phase 3 | 77 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 51 |
| CBL-514, placebo + CBL-514, placebo + CBL-514 | Caliway Biopharmaceuticals | Phase 1 | 32 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 2 | 51 |
| CBL-514 Injection | Caliway Biopharmaceuticals | Phase 3 | 76 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 51 |
| CBL-514 | Caliway Biopharmaceuticals | Phase 2 | 51 |
| CBL-514 injection + CBL-A1 Injection + CBL-A2 Injection + 0.9% Sodium Chloride | Caliway Biopharmaceuticals | Phase 2 | 51 |